New Targeted Therapies for Thyroid Cancer

被引：55

作者：

Antonelli, Alessandro ^{[1
]}

Fallahi, Poupak ^{[1
]}

Ferrari, Silvia M. ^{[1
]}

Ruffilli, Ilaria ^{[1
]}

Santini, Francesca ^{[1
]}

Minuto, Michele ^{[2
]}

Galleri, David ^{[2
]}

Miccoli, Paolo ^{[2
]}

机构：

[1] Univ Pisa, Sch Med, Dept Internal Med, I-56100 Pisa, Italy

[2] Univ Pisa, Sch Med, Dept Surg, I-56100 Pisa, Italy

来源：

CURRENT GENOMICS | 2011年 / 12卷 / 08期

关键词：

Anaplastic thyroid cancer; targeted molecular therapies; tyrosine kinase inhibitors; aurora kinase inhibitors; peroxisome proliferator-activated receptor-gamma; RET; BRAF; VEGFR; PHASE-II TRIAL; SIGNALING PATHWAY; CARCINOMA; RET; PAPILLARY; SORAFENIB; MUTATIONS; THIAZOLIDINEDIONES; ASSOCIATION; VANDETANIB;

D O I：

10.2174/138920211798120808

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (BRAF V600E, RET/PTC) or signaling kinases [vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR)] involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies (sorafenib, sunitinib, axitinib, imanitib, vandetanib, pazopanib, gefitinib) in stabilizing the course of the disease. Until now, however, no consensus guidelines have been established for patient selection and more data on toxicities and side effects are needed to be collected.

引用

页码：626 / 631

页数：6

共 54 条

[1]

Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site [J].

Anders, J ;

Kjær, S ;

Ibáñez, CF .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (38) :35808-35817

[2]

Dedifferentiated thyroid cancer: A therapeutic challenge [J].

Antonelli, Alessandro ;

Fallahi, Poupak ;

Ferrari, Silvia Martina ;

Carpi, Angelo ;

Berti, Piero ;

Materazzi, Gabriele ;

Minuto, Michele ;

Guastalli, Mario ;

Miccoli, Paolo .

BIOMEDICINE & PHARMACOTHERAPY, 2008, 62 (08) :559-563

[3]

Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration [J].

Antonelli, Alessandro ;

Ferrari, Silvia Martina ;

Fallahi, Poupak ;

Berti, Piero ;

Materazzi, Gabriele ;

Marchetti, Ivo ;

Ugolini, Clara ;

Basolo, Fulvio ;

Miccoli, Paolo ;

Ferrannini, Ele .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 159 (03) :283-291

[4]

Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests [J].

Antonelli, Alessandro ;

Ferrari, Silvia Martina ;

Fallahi, Poupak ;

Berti, Piero ;

Materazzi, Gabriele ;

Barani, Lucio ;

Marchetti, Ivo ;

Ferrannini, Ele ;

Miccoli, Paolo .

CLINICAL ENDOCRINOLOGY, 2008, 69 (01) :148-152

[5]

Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer [J].

Antonelli, Alessandro ;

Bocci, Guido ;

La Motta, Concettina ;

Ferrari, Silvia Martina ;

Fallahi, Poupak ;

Fioravanti, Anna ;

Sartini, Stefania ;

Minuto, Michele ;

Piaggi, Simona ;

Corti, Alessandro ;

Ali, Greta ;

Berti, Piero ;

Fontanini, Gabriella ;

Danesi, Romano ;

Da Settimo, Federico ;

Miccoli, Paolo .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (02) :E288-E296

[6]

Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells [J].

Antonelli, Alessandro ;

Ferrari, Silvia Martina ;

Fallahi, Poupak ;

Berti, Piero ;

Materazzi, Gabriele ;

Minuto, Michele ;

Giannini, Riccardo ;

Marchetti, Ivo ;

Barani, Lucio ;

Basolo, Fulvio ;

Ferrannini, Ele ;

Miccoli, Paolo .

CLINICAL ENDOCRINOLOGY, 2009, 70 (06) :946-953

[7]

Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[8]

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study [J].

Bible, Keith C. ;

Suman, Vera J. ;

Molina, Julian R. ;

Smallridge, Robert C. ;

Maples, William J. ;

Menefee, Michael E. ;

Rubin, Joseph ;

Sideras, Kostandinos ;

Morris, John C., III ;

McIver, Bryan ;

Burton, Jill K. ;

Webster, Kevin P. ;

Bieber, Carolyn ;

Traynor, Anne M. ;

Flynn, Patrick J. ;

Goh, Boon Cher ;

Tang, Hui ;

Ivy, Susan Percy ;

Erlichman, Charles .

LANCET ONCOLOGY, 2010, 11 (10) :962-972

[9]

Methods and goals for the use of in vitro and in vivo chemosensitivity testing [J].

Blumenthal, Rosalyn D. ;

Goldenberg, David M. .

MOLECULAR BIOTECHNOLOGY, 2007, 35 (02) :185-197

[10]

Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf [J].

Brummer, T ;

Naegele, H ;

Reth, M ;

Misawa, Y .

ONCOGENE, 2003, 22 (55) :8823-8834

← 1 2 3 4 5 6 →